Multicolored MIS-C, a single-centre cohort study.
COVID-19 in children
MIS-C
Multisystem inflammatory syndrome in children
SARS-CoV-2
Journal
BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804
Informations de publication
Date de publication:
21 04 2023
21 04 2023
Historique:
received:
01
09
2022
accepted:
06
04
2023
medline:
25
4
2023
pubmed:
22
4
2023
entrez:
21
04
2023
Statut:
epublish
Résumé
The aim of this study was to investigate the clinical and laboratory parameters that can predict the severity of Multisystem Inflammatory Syndrome in Children (MIS-C) at admission. We conducted a single-center, partly retrospective, partly prospective, observational cohort study between November 1, 2020 and December 31, 2021, which included patients aged from 1 month to 19 years, meeting the diagnostic criteria of MIS-C. We categorized the patients into three subgroups based on clinical and laboratory markers and assessed the predictive value of these factors in terms of ICU administration and cardiac abnormalities. 53 patients were classified in the following subgroups: Kawasaki-like disease (group 1) (47.2%, n = 25), shock with or without acute cardiac dysfunction (group 2) (32%, n = 17), fever and inflammation (group 3) (20.8%, n = 11). Subgroup analysis revealed that patients with shock and KD at initial presentation had significantly more severe manifestation of MIS-C requiring intensive care unit (ICU) treatment. Of the initial laboratory values, only CRP showed a significant difference between the 3 clinical groups, being lower in group 3. 52.6% of patients were admitted to the ICU. The median length of ICU stay was 3 days (range 3-20). ICU admission was more likely in patients with shortness of breath, renal failure (AKI) and patients with significantly increased concentrations of ferritin, D-dimer, INR and significantly milder increase concentration of fibrinogen. We found that fibrinogen and ferritin levels are independent risk factors for ICU admission. Cardiac abnormalities were found in 56.6% of total (30/53), with the following findings: decreased left ventricular function (32%), coronary abnormality (11.3%), pericardial effusion (17%), arrhythmia (32.1%) and mitral regurgitation (26.6%). Diarrhea and conjunctivitis at the initial presentation with significantly elevated CRP, Pro-BNP and blood pH concentrations were found to be a potential predisposing factor for decreased cardiac function while Pro-BNP and pH were independent risk factors for MIS-C. Regardless of the initial symptoms of MIS-C, the outcome was generally favorable. Clinical characteristics and baseline laboratory values may help identify patients at increased risk for severe disease outcome, such as need for intensive care, presence of shock and decreased cardiac function. Participation consent was not reqired and ethical considerations were unnecessary, since we did not perform any extra interventions, only the necessary and usual therapeutic and diagnostic methods were used.
Sections du résumé
BACKGROUND
The aim of this study was to investigate the clinical and laboratory parameters that can predict the severity of Multisystem Inflammatory Syndrome in Children (MIS-C) at admission.
METHODS
We conducted a single-center, partly retrospective, partly prospective, observational cohort study between November 1, 2020 and December 31, 2021, which included patients aged from 1 month to 19 years, meeting the diagnostic criteria of MIS-C. We categorized the patients into three subgroups based on clinical and laboratory markers and assessed the predictive value of these factors in terms of ICU administration and cardiac abnormalities.
RESULTS
53 patients were classified in the following subgroups: Kawasaki-like disease (group 1) (47.2%, n = 25), shock with or without acute cardiac dysfunction (group 2) (32%, n = 17), fever and inflammation (group 3) (20.8%, n = 11). Subgroup analysis revealed that patients with shock and KD at initial presentation had significantly more severe manifestation of MIS-C requiring intensive care unit (ICU) treatment. Of the initial laboratory values, only CRP showed a significant difference between the 3 clinical groups, being lower in group 3. 52.6% of patients were admitted to the ICU. The median length of ICU stay was 3 days (range 3-20). ICU admission was more likely in patients with shortness of breath, renal failure (AKI) and patients with significantly increased concentrations of ferritin, D-dimer, INR and significantly milder increase concentration of fibrinogen. We found that fibrinogen and ferritin levels are independent risk factors for ICU admission. Cardiac abnormalities were found in 56.6% of total (30/53), with the following findings: decreased left ventricular function (32%), coronary abnormality (11.3%), pericardial effusion (17%), arrhythmia (32.1%) and mitral regurgitation (26.6%). Diarrhea and conjunctivitis at the initial presentation with significantly elevated CRP, Pro-BNP and blood pH concentrations were found to be a potential predisposing factor for decreased cardiac function while Pro-BNP and pH were independent risk factors for MIS-C. Regardless of the initial symptoms of MIS-C, the outcome was generally favorable.
CONCLUSIONS
Clinical characteristics and baseline laboratory values may help identify patients at increased risk for severe disease outcome, such as need for intensive care, presence of shock and decreased cardiac function.
TRIAL REGISTRATION
Participation consent was not reqired and ethical considerations were unnecessary, since we did not perform any extra interventions, only the necessary and usual therapeutic and diagnostic methods were used.
Identifiants
pubmed: 37085781
doi: 10.1186/s12887-023-03997-0
pii: 10.1186/s12887-023-03997-0
pmc: PMC10119512
doi:
Substances chimiques
Fibrinogen
9001-32-5
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
190Informations de copyright
© 2023. The Author(s).
Références
Acta Cardiol Sin. 2015 Nov;31(6):485-93
pubmed: 27122912
J Pediatr Intensive Care. 2021 Feb 24;11(3):259-264
pubmed: 35928043
Pediatr Cardiol. 2021 Jan;42(1):19-35
pubmed: 33015722
Pediatr Crit Care Med. 2021 Mar 1;22(3):e178-e191
pubmed: 33003176
Nat Rev Immunol. 2020 Aug;20(8):453-454
pubmed: 32546853
Pediatrics. 2020 Dec;146(6):
pubmed: 32879033
Lancet. 2020 May 23;395(10237):1607-1608
pubmed: 32386565
Lancet Child Adolesc Health. 2021 Feb;5(2):133-141
pubmed: 32956615
Circulation. 2017 Apr 25;135(17):e927-e999
pubmed: 28356445
Lancet. 2020 Jun 6;395(10239):1771-1778
pubmed: 32410760
JAMA. 2021 Mar 2;325(9):855-864
pubmed: 33523115
Ann Surg. 2021 Apr 1;273(4):e146-e148
pubmed: 33074884
Eur J Pediatr. 2021 Jul;180(7):2019-2034
pubmed: 33599835
J Pediatr. 2020 Nov;226:45-54.e1
pubmed: 32768466
Children (Basel). 2020 Jul 01;7(7):
pubmed: 32630212
JAMA. 2020 Jul 21;324(3):259-269
pubmed: 32511692
N Engl J Med. 2020 Jul 23;383(4):334-346
pubmed: 32598831
Cell. 2020 Nov 12;183(4):968-981.e7
pubmed: 32966765
Arthritis Rheumatol. 2022 Apr;74(4):e1-e20
pubmed: 35118829
Circulation. 2021 Jan 5;143(1):78-88
pubmed: 33166178
N Engl J Med. 2020 Jul 23;383(4):347-358
pubmed: 32598830
Lancet Child Adolesc Health. 2021 May;5(5):323-331
pubmed: 33711293
Arthritis Rheumatol. 2021 Apr;73(4):e13-e29
pubmed: 33277976
Am J Emerg Med. 2021 Nov;49:62-70
pubmed: 34082189
JAMA. 2020 Jul 21;324(3):294-296
pubmed: 32511676
EClinicalMedicine. 2020 Sep;26:100527
pubmed: 32923992
J Med Virol. 2021 Jul;93(7):4358-4369
pubmed: 33739452
Pediatr Infect Dis J. 2020 Nov;39(11):e340-e346
pubmed: 32925547
MMWR Morb Mortal Wkly Rep. 2020 Aug 14;69(32):1074-1080
pubmed: 32790663
JAMA Pediatr. 2020 Sep 01;174(9):882-889
pubmed: 32320004